Skip to main content
SpringerLink
Log in

Effects of chronic neuroleptic treatment on dopamine release: Insights from studies using 3-methoxytyramine

  • Published:
Journal of Neural Transmission Aims and scope Submit manuscript

Summary

Antipsychotic medications appear to exert their therapeutic effects by blocking D2 receptors. While D2 blockade occurs rapidly, reduction in psychotic symptoms is often delayed. This time discrepancy has been attributed to the relatively slow development of depolarization inactivation (DI) of dopaminergic neurons. The reduced firing rates associated with DI has been hypothesized to reduce dopamine release and thus psychotic symptoms. Studies assessing changes in dopamine release during chronic neuroleptic treatment, using microdialysis and voltammetry, have been inconsistent. This may be due to methodological differences between studies, the invasive nature of these procedures, or other confounds.

To investigate the effects of DI on dopamine release, 3-MT accumulation, an index of dopamine release that does not involve disruption of brain tissue, was measured during acute and chronic neuroleptic treatment. These results are compared with those using other techniques. 3-MT levels remained elevated after chronic treatment, suggesting that DI does not markedly reduce release. Regulation of dopamine release during DI was examined using two techniques known to block dopamine neuronal impulse flow. 3-MT levels were markedly reduced by both, implying that DI does not alter the portion of dopamine release mediated by neuronal impulse flow. Overall, studies to date suggest that the delayed therapeutic effects of neuroleptics are not due to reductions in impulse dependent dopamine release. Recent studies using a neurodevelopmental animal model of schizophrenia have pointed to altered pre- and post-synaptic indices of dopamine neurotransmission. The results suggest that neuroleptics may exert their therapeutic effects, in part, by limiting the fluctuations in dopamine release, and raise new issues for future research.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Altar A, Neve K, Loughlin SE, Marshall JF, Fallon JH (1983) The crossed mesostriatal projection: neurochemistry and developmental response to lesion. Brain Res 279: 1–8

    Google Scholar 

  • Altar CA, Wasely AM, Liebman J, Gerhardt S, Kim H, Welch JJ, Wood PL (1986) CGS 10746B: an atypical antipsychotic candidate that selectively decreases dopamine release at behaviorally effective doses. Life Sci 39: 699–705

    Google Scholar 

  • Altar CA, Wasely AM, Boyar WC, Liebman J, Gerhardt S, Wood PL (1988) Dopamine neurochemical profile of atypical antipsychotics resembles that of D-1 antagonists. Naunyn Schmiedebergs Arch Pharmacol 338: 162–168

    Google Scholar 

  • Anden NE, Magnusson T, Stock G (1973) Effects of drugs influencing monoamine mechanisms on the increase in brain dopamine produced by axotomy of treatment with gammahydroxybutyric acid. Naunyn Schmiedebergs Arch Pharmacol 278: 363–372

    Google Scholar 

  • Anden NE, Grenhoff J, Svensson TH (1988) Does treatment with haloperidol for 3 weeks produce depolarization block in midbrain dopamine neurons of unanaesthetized rats. Psychopharmacology 96: 558–560

    Google Scholar 

  • Bannon MJ, Michaud RL, Roth R (1981) Mesocortical dopamine neurons. Lack of autoreceptors modulating dopamine synthesis. Mol Pharmacol 19: 270–275

    Google Scholar 

  • Bannon MJ, Chiodo LA, Bunney EB, Wolf ME, Grace AA, Bunney BS, Roth RH (1984) In vivo biochemical and electrophysiological studies on the distribution and pharmacology of dopamine autoreceptors, midbrain dopamine cell activity. In: Usdin E, Carlsson A, Dahlstrom A, Engel J (eds) Catecholamines: neuropharmacology and central nervous system: theoretical aspects. Alan R Liss, New York, pp 25–36

    Google Scholar 

  • Bettini E, Ceci A, Spinelli R, Samanin R (1987) Neuroleptic-like effects of the 1-isomer of fenfluramine on striatal dopamine release in freely moving rats. Biochem Pharmacol 36: 2387–2391

    Google Scholar 

  • Blaha CD, Lane RF (1987) Chronic treatment with classical and atypical antipsychotic drugs differentially decreases dopamine release in striatum and nucleus accumbens in vivo. Neurosci Lett 78: 199–204

    Google Scholar 

  • Blank CL, Sasa S, Isernhagen R, Meyerson LR, Wassil D, Wong P, Modak AT, Stavinoha WB (1979) Levels of norepinephrine and dopamine in mouse brain regions following microwave irradiation-rapid post-mortem degradation of striatal dopamine in decapitated animals. J Neurochem 33: 213–219

    Google Scholar 

  • Brown EE, Damsma G, Cumming P, Fibiger HC (1991) Interstitial 3-methoxytyramine reflects striatal dopamine release: an in vivo microdialysis study. J Neurochem 57: 701–707

    Google Scholar 

  • Bunney BS (1988) Effects of acute and chronic neuroleptic treatment on the activity of midbrain dopamine neurons. Ann NY Acad Sci 537: 77–85

    Google Scholar 

  • Bunney BS, Grace AA (1978) Acute and chronic haloperidol treatment: comparison of effects on nigral dopaminergic cell activity. Life Sci 23: 1715–1728

    Google Scholar 

  • Butcher SP, Fairbrother IS, Kelly JS, Arbuthnott GW (1990) Effects of selective monoamine oxidase inhibitors on the in vivo release and metabolism of dopamine in the rat striatum. J Neurochem 55, 3: 981–988

    Google Scholar 

  • Buu NT (1989) Modification of vesicular dopamine and norepinephrine by monoamine oxidase inhibitors. Biochem Pharmacol 38: 1685–1692

    Google Scholar 

  • Carboni E, Tanda G, Di Chiara (1992) Extracellular striatal concentrations of endogenous 3,4-dihydroxyphenylalanine in the absence of a decarboxylase inhibitor: a dynamic index of dopamine synthesis in vivo. J Neurochem 59: 2230–2236

    Google Scholar 

  • Carr VJ (1983) Recovery from schizophrenia: a review of patterns of psychosis. Schizophr Bull 9: 95–121

    Google Scholar 

  • Cenci MA, Kalen P, Mandel RJ, Bjorklund A (1992) Regional differences in the regulation of dopamine and noradrenaline release in medial frontal cortex, nucleus accumbens and caudate-putamen: a microdialysis study in the rat. Brain Res 581: 217–228

    Google Scholar 

  • Chai B, Meltzer HY (1992) The effect of chronic clozapine on basal dopamine release and apomophine-induced DA release in the striatum and nucleus accumbens as measured by in vivo brain microdialysis. Neurosci Lett 136: 47–50

    Google Scholar 

  • Chen J, Paredes W, Gardner EL (1991) Chronic treatment with clozapine selectively decreases basal dopamine release in nucleus accumbens but not in caudate-putamen as measured by in vivo microdialysis: further evidence for depolarization block. Neurosci Lett 122: 127–131

    Google Scholar 

  • Chen J, Paredes W, van Praag HM, Gardner EL (1992a) Serotonin denervation enhances responsiveness of presynaptic dopamine efflux to acute clozapine in nucleus accumbens but not in caudate-putamen. Brain Res 582: 173–179

    Google Scholar 

  • Chen J, Ruan D, Paredes W, Gardner EL (1992b) Effects of acute and chronic clozapine on dopaminergic function in medial prefrontal cortex of awake, freely moving rats. Brain Res 571: 235–241

    Google Scholar 

  • Chiodo LA, BS Bunney (1983) Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A-9 and A-10 midbrain dopaminergic neurons. J Neurosci 3: 1607–1619

    Google Scholar 

  • Chiodo LA, Bunney BS (1985) Possible mechanisms by which repeated clozapine administration differentially affects the activity of two subpopulations of midbrain dopamine neurons. J Neurosci 5: 2538–2544

    Google Scholar 

  • Chrapusta SJ, Karoum F, Egan MF, Wyatt RJ (1992) gamma-Butyrolactone-sensitive and -insensitive dopamine release, and their relationship to dopamine metabolism in three rat brain regions. Eur J Pharmacol 222: 129–135

    Google Scholar 

  • Chrapusta SJ, Karoum F, Egan MF, Wyatt RJ (1993) Haloperidol and clozapine increase intraneuronal dopamine metabolism, but not gamma-butyrolactone-resistant dopamine release. Eur J Pharmacol 233: 135–142

    Google Scholar 

  • Chrapusta SJ, Egan MF, Wyatt RJ (1996) Chronic haloperidol changes relationship between nigral and striatal dopamine release and metabolism in the intact rat. Neurosci Lett (submitted)

  • Commissiong JW (1985) Monoamine metabolites: their relationship and lack of relationship to monoaminergic neuronal activity. Biochem Pharmacol 34: 1127–1131

    Google Scholar 

  • Compton DR, Johnson KM (1989) Effects of acute and chronic clozapine and haloperidol on in vitro release of acetylcholine and dopamine from striatum and nucleus accumbens. J Pharmacol Exp Ther 248: 521

    Google Scholar 

  • Creese I, Burt DR, Snyder SH (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192: 481–483

    Google Scholar 

  • Cumming P, Brown E, Damsma G, Fibiger H (1992) Formation and clearance of interstitial metabolites of dopamine and serotonin in the rat striatum: an in vivo microdialysis study. J Neurochem 59(5): 1905–1914

    Google Scholar 

  • Drew KL, O'Connor WT, Kehr J, Ungerstedt U (1990) Regional specific effects of clozapine and haloperidol on GABA and dopamine release in rat basal ganglia. Eur J Pharmacol 187: 385–397

    Google Scholar 

  • Egan MF, Karoum F, Wyatt RJ (1991) Effects of acute and chronic clozapine and haloperidol administration on 3-methoxytyramine accumulation in rat prefrontal cortex, nucleus accumbens and striatum. Eur J Pharmacol 199: 191–199

    Google Scholar 

  • Egan MF, Chrapusta SJ, Karoum F, Wyatt RJ (1996) Dopamine release mediated by impulse flow through the medial forebrain bundle is not altered in the striatum and nucleus accumbens following chronic haloperidol treatment. Neuropsychopharmacology 14: 211–223

    Google Scholar 

  • Ewing AL, Wightman RM, Dayton MA (1984) In vivo voltammetry with electrodes that discriminate between dopamine and ascorbate. Brain Res 249: 361–370

    Google Scholar 

  • Gerfen CR, Engber TM, Mahan LC, Susel Z, Chase TN, Monsma FJ, Sibley DR (1990) D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250: 1429–1432

    Google Scholar 

  • Gerhardt G, Oke AF, Nagy G, Moghaddam B, Adams RN (1984) Nafion-coated electrodes with high selectivity for CNS neurochemistry. Brain Res 290: 390–395

    Google Scholar 

  • Gerhardt G, Pang K, Rose GM (1987) In vivo electrochemical demonstration of the presynaptic actions of phencylidine in rat caudate nucleus. J Pharmacol Exp Ther 241: 714–721

    Google Scholar 

  • Georgieva J, Luthman J, Mohringe B, Mangusson O (1993) Tissue and microdialysate changes after repeated and permanent probe implantation in the striatum of freely moving rats. Brain Res Bull 31(5): 463–470

    Google Scholar 

  • Gessa GL, Vargiu L, Crabai F, Boero GC, Caboni F, Cambra R (1966) Selective increase of brain dopamine induced by gamma-hydroxybutyrate. Life Sci 5: 1921–1930

    Google Scholar 

  • Glovinsky D, Kirch DG, Wyatt RJ (1992) Early antipsychotic response to resumption of neuroleptics in drug-free chronic schizophrenic patients. Biol Psychiatry 31: 968–970

    Google Scholar 

  • Glowinski J, Cheramy A, Romo R, Barbeito L (1988) Presynaptic regulation of dopamine transmission in the striatum. Cell Mol Neurobiol 8: 175–180

    Google Scholar 

  • Gonon FG, Buda MJ (1985) Regulation of dopamine release by impulse flow and by autoreceptors as studied by in vivo voltammetry in the rat striatum. Neuroscience 14: 765–774

    Google Scholar 

  • Grace AA (1991) Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 41(1): 1–24

    Google Scholar 

  • Grace AA (1992) The depolarization block hypothesis of neuroleptic action: implications for the etiology and treatment of schizophrenia. J Neural Transm [Suppl] 36: 91–131

    Google Scholar 

  • Grace AA, Bunney BS (1986) Induction of depolarization block in midbrain dopaminergic neurons by repeated administration of haloperidol: analysis using in vivo intracellular recording. J Pharmacol Exp Ther 238: 1092–1100

    Google Scholar 

  • Gripenberg J, Heinmen E, Jansson SE (1980) Uptake of radiocalcium by nerve endings isolated from rat brain: kinetic studies. Br J Pharmacol 71: 265–271

    Google Scholar 

  • Groppetti AM, Parenti CL, Galli A, Bugatti F, Cattabeni AM, DiGiulio G, Racagni G (1978) 3-Methoxytyramine and different neuroleptics: dissociation from HVA and DOPAC. Life Sci 23: 1763

    Google Scholar 

  • Gudelsky GA, Nwajei E, Defife K, Nash JF (1992) Interaction of amfonelic acid with antipsychotic drugs on dopaminergic neurons. Synapse 12: 304–311

    Google Scholar 

  • Hand TH, Hu HT, Wang RX (1987) Differential effects of acute clozapine and haloperidol on the activity of ventral tegmental (A10) and nigrostriatal (A9) dopamine neurons. Brain Res 415: 257

    Google Scholar 

  • Heal DJ, Frankland ATJ, Buckett WR (1990) A new and highly sensitive method for measuring 3-methoxytyramine using HPLC with elctrochemical detection. Studies with drugs which alter dopamine metabolism in the brain. Neuropharmacology 29: 1141–1150

    Google Scholar 

  • Hernandez L, Hoebel B (1989) Haloperidol given chronically decreases basal dopamine in the prefrontal cortex more than the striatum or nucleus accumbens as simultaneously measured by microdialysis. Brain Res Bull 22: 763–769

    Google Scholar 

  • Hollerman JR, Grace AA (1989) Acute haloperidol administration induces depolarization block of nigral dopamine neurons in rats after partial dopamine lesions. Neurosci Lett 98: 82–88

    Google Scholar 

  • Hollerman JR, Abercrombie ED, Grace AA (1992) Electrophysiological, biochemical, and behavioral studies of acute halperidol-induced depolarization block of nigral dopamine neurons. Neuroscience 47: 589–601

    Google Scholar 

  • Huff RM, Adams RN (1984) Dopamine release in n. accumbens and striatum by clozapine: simulataneous monitoring by in vivo electrochemistry. Neuropharmacology 19: 587

    Google Scholar 

  • Ichikawa J, Meltzer HY (1990a) The effect of chronic clozapine and haloperidol on basal dopamine release and metabolism in rat striatum and nucleus accumbens studied by in vivo microdialysis. Eur J Pharmacol 176: 371–374

    Google Scholar 

  • Ichikawa J, Meltzer HY (1990b) Apomorphine does not reverse reduced basal dopamine release in rat striatum and nucleus accumbens after chronic haloperidol treatment. Brain Res 507: 138–142

    Google Scholar 

  • Ichikawa J, Meltzer HY (1991) Differential effects of repeated treatment with haloperidol and clozapione on dopamine release and metabolism in the striatum and the nucleus accumbens. J Pharmacol Exp Ther 256: 348–357

    Google Scholar 

  • Ichikawa J, Meltzer HY (1992) The effect of chronic atypical antipsychotic drugs and haloperidol on amphetamine-induced dopamine release in vivo. Brain Res 574: 98–104

    Google Scholar 

  • Imperato A, Di Chiara G (1984) Transstriatal dialysis coupled to reverse phase high performance liquid chromatography with electrochemical detection: a new method for the study of the in vivo release of endogenous dopamine and metabolites. J Neurosci 4: 966–977

    Google Scholar 

  • Imperato A, DiChiara G (1985) Dopamine release and metabolism in awake rats as studied by trans-striatal dialysis. J Neurosci 5: 297

    Google Scholar 

  • Imperato A, Angelucci L (1989) The effects of clozapine and fluperlapine on the in vivo release and metabolism of dopamine in the striatum and in the prefrontal cortex of freely moveing rats. Psychopharmacol Bull 25: 383–389

    Google Scholar 

  • Invernizzi R, Morali F, Possi L, Samanin R (1990) Effects of acute and chronic clozapine on dopamine release and metabolism in the striatum and nucleus accumbens of conscious rats. Br J Pharmacol 99: 741–749

    Google Scholar 

  • Jaskiw GE, Karoum FK, Weinberger DR (1990) Persistent elevations in dopamine and its metabolites in the nucleus accumbens after mild subchronic stress in rats with ibotenic acid lesions of the medial prefrontal cortex. Brain Res 534: 321–323

    Google Scholar 

  • Justice JB (1993) Quantitative microdialysis of neurotransmitters. J Neurosci Meth 48(3): 263–276

    Google Scholar 

  • Kaakkola S, Mannisto PT, Nissinen E (1987) Membrane-bound and soluble catecholo-methyl-transferase after selective neuronal lesions in the rat. J Neural Transm 69: 221–228

    Google Scholar 

  • Kalivas PW, Duffy P (1991) A comparison of axonal and somatodendritic dopamine release using in vivo dialysis. J Neurochem 56: 961–967

    Google Scholar 

  • Kane J, Honigfeld G, Singer J, Meltzer HY (1988) Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 45: 789

    Google Scholar 

  • Karoum F, Egan MF (1992) Dopamine release and metabolism in the rat frontal cortex, nucleus accumbens, and striatum: a comparison of acute clozapine and haloperidol. Br J Pharmacol 105: 703–707

    Google Scholar 

  • Karoum FK, Chrapusta S, Egan MF, Wyatt RJ (1994a) Three-methoxytyramine is the major metabolite of dopamine in the rat prefrontal cortex: reassessment of the effects of neuroleptics on dopamine release and metabolism in the frontal cortex, nucleus accumbens, and striatum by a simple two poor model. J Neurochem 63: 972–979

    Google Scholar 

  • Karoum F, Chrapusta SJ, Brinjak R, Hitri A, Wyatt RJ (1994b) Regional effects of amphetamine, cocaine, nomifensine and GBR 12909 on the dynamics of dopamine release and metabolism in the rat brain. Br J Pharmacol 113: 1391–1399

    Google Scholar 

  • Keck PE, Cohen BM, Baldessarinin RJ, McElroy SL (1989) Time course of antipsychotic effects of neuroleptic drugs. Am J Psychiatry 146: 1289–1292

    Google Scholar 

  • Kehr J (1993) A survey on quantitative microdialysis: theoretical models and practical implications. J Neurosci Meth 48: 251–261

    Google Scholar 

  • Kuczenski R, Segal DS (1989) Concomitant characterization of behavioral and striatal neurotransmitter response to amphetamine using in vivo microdialysis. J Neurosci 9(6): 2051–2065

    Google Scholar 

  • Kuczenski R, Segal DS (1992) Differential effects of amphetamine and dopamine uptake blockers (cocaine, nomifensine) on caudate and accumbens dialysate dopamine and 3-methoxytyramine. J Pharmacol Exp Ther 262: 1085–1094

    Google Scholar 

  • Lane RF, Blaha CD (1987) Chronic haloperidol decreases dopamine release in striatum and nucleus accumbens in vivo: depolarization block as a possible mechanism of action. Brain Res Bull 18: 135–142

    Google Scholar 

  • Leslie SW, Woodward JJ, Wicox RE (1985) Correlation of rates of calcium entry and endogenous dopamine release in mouse striatal synaptosomes. Brain Res 325: 99–105

    Google Scholar 

  • Lillrank SM, Lipska BK, Weinberger DR (1995) Neurodevelopmental animal models of schizophrenia. Clin Neurosci 3: 98–104

    Google Scholar 

  • Lipska BK, Jaskiw GE, Weinberger DR (1993) Postpubertal emergence of hyper-responsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: a potential animal model of schizophrenia. Psychopharmacology 9: 67–75

    Google Scholar 

  • Lipska BK, Weinberger DR (1993a) Delayed effects of neonatal hippocampal damage on haloperidol-induced catalepsy and apomorphine-induced stereotypic behaviors in the rat. Dev Brain Res 75: 213–222

    Google Scholar 

  • Lipska BK, Weinberger DR (1993b) Cortical regulation of the mesolimbic dopamine system: implications for schizophrenia. In: Kalivas PW, Barnes CD (eds) Limbic circuits and neuropsychiatry. CRC Press, Boca Raton, pp 329–349

    Google Scholar 

  • Lipska BK, Chrapusta SJ, Egan MF, Weinberger DR (1995) Neonatal excitotoxic ventral hippocampal damage alters dopamine response to mild repeated stress and to chronic haloperidol. Synapse 20: 125–130

    Google Scholar 

  • Loughlin SE, Fallon JH (1982) Mesostriatal projections from ventral tegmentum and dorsal raphe: cells project ipsilaterally or contralaterally but notbilaterally. Neurosci Lett 32: 11–16

    Google Scholar 

  • May LJ, Wightman RM (1989) Effects of D-2 antagonists on frequency-dependent stimulated dopamine overflow in nucleus accumbens and caudate-putamen. J Neurochem 53(3): 898–906

    Google Scholar 

  • Meltzer HY, Chai BL, Thompson PA, Yamamoto BK (1994) Effects of scopolamine on the efflux of dopamine and its metabolites after clozapine, haloperidol, of thioridazine. J Pharmacol Exp Ther 268: 1542–1461

    Google Scholar 

  • Moghaddam B, Bunney BS (1989) Ionic composition of microdialysis perfusing soution alters the pharmacological responsivenessand basal outflow of striatal dopamine. J Neurochem 53: 652–654

    Google Scholar 

  • Moghaddam B, Bunney BS (1990) Acute effects of typical and atypical antipsychotic drugs on the release of DA from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J Neurochem 54(5): 1755

    Google Scholar 

  • Moghaddam B, Bunney BS (1991) Utilization of microdialysis for assessing the release of mesotelencephalic dopamine following clozapine and other antipsychotic drugs. Prog Neuropsychopharmacol Biol Psychiatry 14: S51-S57

    Google Scholar 

  • Moghaddam B, Bunney BS (1993) Depolarization inactivation of dopamine neurons: terminal release characteristics. Synapse 14: 195–200

    Google Scholar 

  • Mount H, Welner S, Quirion R, Boksa P (1989) Glutamate stimulation of [3H]dopamine release from dissociated cell cultures of rat ventral mesencephalon. J Neurochem 52(4): 1300–1310

    Google Scholar 

  • Mueller K (1986) In vivo voltammetric recording with nafion-coated carbon paste electrodes: additional evidence that ascorbic acid release is monitored. Pharmacol Biochem Behav 25: 325–328

    Google Scholar 

  • Naudon L, Dourmap N, Leroux-Nicollet I, Costentin J (1992) Kainic acid lesion of the striatum increases dopamine release but reduces 3 methoxytyramine level. Brain Res 572: 247–249

    Google Scholar 

  • Narahashi T (1974) Chemicals as tools in the study of excitable membranes. Physiol Rev 54: 813–877

    Google Scholar 

  • Nieoullon A, Cheramy A, Glowinski J (1978) Release of dopamine evoked by electrical stimulation of the motor and visual areas of the cerebral cortex in both caudate nuclei and in the substantia nigra in the cat. Brain Res Bull 11: 671–680

    Google Scholar 

  • O'Connor WT, Drew KL, Ungerstedt U (1989) Differences in dopamine release and metabolism in rat striatal subregions following acute clozapine using in vivo microdialysis. Neurosci Lett 98: 211–216

    Google Scholar 

  • Osborne PG, O'Connor WT, Drew KL, Ungerstedt U (1990) An in vivo microdialysis characterization of extracellular dopamine and GABA in dorsolateral striatum of awake freely moving and halothane anaesthetised rats. J Neurosci Meth 34: 99–105

    Google Scholar 

  • Patterson TA, Schenk JO (1991) Effects of acute and chronic systemic administration of some typical antipsychotic drugs on turnover of dopamine and potassium ioninduced release of dopamine in the striatum of the rat in vivo. Neuropharmacology 30: 943–952

    Google Scholar 

  • Ponzio F, Achilli G, Perego C, Algeri S (1981) Differential effects of certain dopaminergic drugs in the striatal concentrations of dopamine metabolites with special reference to 3-methoxytyramine. Neurosci Lett 27: 61–67

    Google Scholar 

  • Puglisi-Allegra S, Imperato A, Angelucci L, Cabib S (1991) Acute stress induces time-dependent responses in dopamine mesolimbic system. Brain Res 554: 217–222

    Google Scholar 

  • Pycock CJ, Kerwin RW, Carter CJ (1980) Effect of lesion of cortical dopamine terminals on subcortical dopamine in rats. Nature (London) 286: 74

    Google Scholar 

  • Rivest R, Marsden CA (1991) Muscarinic antagonists attenuate the increase in accumbens and striatum dopamine metabolism produced by clozapine but not by haloperidol. Br J Pharmacol 104: 234–238

    Google Scholar 

  • Rivest R, Marsden CA (1992) Differential effects of amfonelic acid on the haloperidol- and clozapine-induced increase in extracellular DOPAC in the nucleus accumbens and the striatum. Synapse 10: 71–78

    Google Scholar 

  • Robinson TE, Whishaw IQ (1988) Normalization of extracellular dopamine in striatum following recovery from a partial unilateral 6-OHDA lesion of the substantia nigra: a microdialysis study in freely moving rats. Brain Res 450: 209–224

    Google Scholar 

  • Saller CF, Salama AI (1986) 3-Methoxytyramine accumulation: effects of typical neuroleptics and various atypical compounds. Naunyn Schmiedebergs Arch Pharmacol 334: 125–136

    Google Scholar 

  • Schmidt CJ, Sullivan CK, Fadayel GM (1994) Blockade of striatal 5-hydroxytryptamine 2 receptors reduces the increase in extracellular concentrations of dopamine produced by the amphetamine analogue 3,4-methylenedioxymethamphetamine. J Neurochem 62: 1382–1389

    Google Scholar 

  • See RE (1991) Striatal dopamine metabolism increases during long-term haloperidol administration in rats but shows tolerance in response to actue challenge with raclopride. Neurosci Lett 129: 265–268

    Google Scholar 

  • See RE (1993) Assessment of striatal extracellular dopamine and dopamine metabolites by microdialysis in haloperidol-treated rats exhibiting oral dyskinesias. Neuropsychopharmacology 9: 101–109

    Google Scholar 

  • See RE, Murray CE (1992) Changes in striatal dopamine release and metabolism during and after subchronic haloperidol administration in rats. Neurosci Lett 142: 100–104

    Google Scholar 

  • See RE, Chapman MA, Meshul CK (1992) Comparsion of chronic intermittent haloperidol and raclopride effects on striatal dopamine release and synaptic ultrastructure in rats. Synapse 12: 147–154

    Google Scholar 

  • Seeman P, Lee T, Chau-Wong M, Wong K (1977) Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261: 717–719

    Google Scholar 

  • Stamford JA, Kruk ZL, Millar J (1988) Actions of dopamine antagonists on stimulated striatal and linbic dopamine release: an in vivo voltammetric study. Br J Pharmacol 94: 924–932

    Google Scholar 

  • Stock G, Magnusson T, Anden NE (1973) Increase in brain dopamine after axotomy or treatment with gammahydroxybutyric acid due to elimination of the nerve impulse flow. Naunyn Schmiedebergs Arch Pharmacol 278: 347–361

    Google Scholar 

  • Tanaka T, Vincent SR, Nomikos GG, Fibiger HC (1992) Effect of quinine on autoreceptor-regulated dopamine release in the rat striatum. J Neurochem 59: 1640–1645

    Google Scholar 

  • Volonté M, Ceci A, Borsini F (1992) Effect of haloperidol and clozapine on (+) SKF 10,047-induced dopamine release: role of 5-HT3 receptors. Eur J Pharmacol 213: 163–164

    Google Scholar 

  • Vulto A, Westenberg HGM, Meijer LBA, Versteeg DHG (1986) The dopamine metabolite 3-methoxytyramine is not a suitable indicator of dopamine release in the rat brain. J Neurochem 47: 1387–1393

    Google Scholar 

  • Waldmeier PC, Lauber J, Blum W, Richter WJ (1981) 3-Methoxytyramine: its suitability as an indicator of synaptic dopamine release. Naunyn Schmiedebergs Arch Pharmacol 315: 219–225

    Google Scholar 

  • Walters JR, Roth RH (1972) Effects of gamma-hydroxybutyrate on dopamine and dopamine metabolites in the rat striatum. Biochem Pharmacol 21: 2111–2121

    Google Scholar 

  • Walters JR, Roth RH (1973) Dopaminergic neurons: similar biochemical and histochemical effects of gamma-hydroxybutyrate and acute lesions of the nigrostriatal pathway. J Pharmacol Exp Ther 186: 630–639

    Google Scholar 

  • Walters JR, Aghajanian GK, Roth RH (1972) Dopaminergic neurons: inhibition of firing by gamma-hydroxybutyrate. Proc Fifth Congr Pharmacol 246–252

  • Westerink BHC (1979) Effects of drugs on the formation of 3-methoxytyramine, a dopamine metabolite, in the substantia nigra, striatum, nucleus accumbens and tuberculum olfactorium of the rat. J Pharm Pharmacol 31: 94–99

    Google Scholar 

  • Westerink BHC, Spaan SJ (1982) On the significance of endogenous 3-methoxytyramine for the effects of centrally acting drugs on dopamine release in the rat brain. J Neurochem 38: 680–686

    Google Scholar 

  • Westerink BHC, DeVries JB (1988) Characterization of in vivo dopamine release as determined by brain microdialysis after acute and subchronic implantations: methodological aspects. J Neurochem 51: 683–687

    Google Scholar 

  • Westerink BHC, Damsma H, Rollema H, DeVries JB, Horn AS (1987) Scope and limitations of in vivo brain dialysis: a comparison of its application to various neurotransmitter systems. Life Sci 41: 1763–1776

    Google Scholar 

  • White FJ, Wang RX (1983a) Comparison of the effects of chronic haloperidol treatment on A-9 and A-10 dopaminergic neurons in the rat. Life Sci 32: 983

    Google Scholar 

  • White FJ, Wang RX (1983b) Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science 221: 1054

    Google Scholar 

  • Wiedemann DJ, Garris PA, Near JA, Wightman RM (1992) Effect of chronic haloperidol treatment on stimulated synaptic overflow of dopamine in the rat striatum. J Pharmacol Exp Ther 261: 574–579

    Google Scholar 

  • Wood PL, Altar CA (1988) Dopamine release in vivo from nigrostriatal mesolimbic and mesocortical neurons: utility of 3-methoxytyramine measurements. Pharmacol Rev 4: 163–187

    Google Scholar 

  • Wood PL, Nair NP, Bozarth M (1982) Striatal 3-methoxytyramine as an index of dopamine release: effects of electrical stimulation. Neurosci Lett 32: 291–294

    Google Scholar 

  • Wood PL, McQuade PS, Etienne P, Lal S, Nair NPV (1983) Differential actions of classical and atypical neuroleptics on mouse nigrostriatal neurons. Prog Neuropsychopharmacol Biol Psychiatry 7: 765–768

    Google Scholar 

  • Wood PL, Kim HS, Marien MR (1987a) Intracerebral dialysis: direct evidence for the utility of 3-MT measurements as an index of dopamine release. Life Sic 41: 1–9

    Google Scholar 

  • Wood PL, Kim HS, Altar CA (1987b) In vivo assessment of dopamine and norepinephrine release in rat neocortex: gas chromatography-mass spectrometry measurement of 3-methoxytyramine and normetanephrine. J Neurochem 48: 574–579

    Google Scholar 

  • Wood PL, Kim HS, Stöcklin K, Rao TS (1988) Dynamics of the striatal 3-MT pool in rat and mouse: species differences as assessed by steady-state measurements and intra-cerebral dialysis. Life Sci 42: 2275–2281

    Google Scholar 

  • Yamamoto BK, Cooperman MA (1994) Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations. J Neurosci 14: 4159–4166

    Google Scholar 

  • Youngren KD, Moghaddam B, Bunney BS, Roth RH (1994) Preferential activation of dopamine overflow in prefontal cortex produced by chronic clozapine treatment. Neurosci Lett 165: 41–44

    Google Scholar 

  • Zetterström T, Sharp T, Ungerstedt U (1985) Effect of neuroleptic durg on striatal dopamine release and metabolism in the awake rat studied by intracerebral dialysis. Eur J Pharmacol 106: 27

    Google Scholar 

  • Zetterström T, Sharp T, Collin AK, Ungerstedt U (1988) In vivo measurement of extracellular dopamine and DOPAC in rat striatum after various dopamine-releasing drugs; implications for the origin of extracellular DOPAC. Eur J Pharmacol 148: 327–334

    Google Scholar 

  • Zhang W, Tilson H, Stachowiak MK, Hong JS (1989) Repeated haloperidol changes basal release of striatal dopamine and subsequent response to haloperidol challenge. Brain Res 484: 389

    Google Scholar 

  • Zigmond MJ, Berger TW, Grace AA, Stricher EM (1989) Compensatory responses to nigrostriatal bundle injury: studies with 6-hydroxydopamine in an animal model of Parkinsonism. Mol Chem Neuropathol 10: 185–200

    Google Scholar 

  • Zigmond MJ, Abercrombie ED, Berger TW, Grace AA, Stricker EM (1990) Compensation after lesions of central dopaminergic neurons. Some clinical and basic implications Trends Neurosci 13(7): 290–295

    Google Scholar 

Download references

Author information

Author notes

  1. M. F. Egan

    Present address: Clinical Brain Disorders Branches, National Institute of Mental Health, Neuroscience Research Center at St. Elizabeth's, Washington, DC, USA

Authors and Affiliations

  1. Neuropsychiatry, National Institute of Mental Health, Neuroscience Research Center at St. Elizabeth's, Washington, DC, USA

    M. F. Egan, S. Chrapusta, F. Karoum & R. Jed Wyatt

  2. Clinical Brain Disorders Branches, National Institute of Mental Health, Neuroscience Research Center at St. Elizabeth's, Washington, DC, USA

    B. K. Lipska

Authors
  1. M. F. Egan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Chrapusta
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Karoum
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B. K. Lipska
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R. Jed Wyatt
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Egan, M.F., Chrapusta, S., Karoum, F. et al. Effects of chronic neuroleptic treatment on dopamine release: Insights from studies using 3-methoxytyramine. J. Neural Transmission 103, 777–805 (1996). https://doi.org/10.1007/BF01273358

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01273358

Keywords

Search

Navigation